Literature DB >> 17073402

Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice.

Amy M Hicks1, Mark C Willingham, Wei Du, Changlee S Pang, Lloyd J Old, Zheng Cui.   

Abstract

SR/CR (spontaneous regression/complete resistance) mice resist multiple types of cancer cells injected at numbers that are lethal to wild type (WT) mice. When the anti-tumor response was examined, leukocytes of the innate immune system, including neutrophils (PMN), macrophages and NK cells, infiltrated the tumor site for a multipronged killing response. Each cell type had independent killing activity against the cancer cells. A second aspect of this multipronged response was that cancer cells could be killed either via necrosis in vivo or via apoptosis by purified macrophages. Lymphoid cells displayed perforin (pfp) and granzymes (gzm) as effector molecules, but macrophages produced reactive oxygen species (ROS) and secreted serine proteases to kill the cancer cells. However, SR/CR macrophages did not use the well-studied tumoricidal mechanism of reactive nitrogen species (RNS) production. We previously demonstrated that macrophages tightly bound cancer cells in rosettes, and we show here that macrophages required contact with the target cells in order to unleash their cytotoxic mechanisms. Once SR/CR mice survived challenge with cancer cells, they produced antibodies that recognized the cancer cells. However, the antibodies were not required for killing by SR/CR macrophages through antibody-dependent cell-mediated cytotoxicity (ADCC) and did not enable wild type macrophages to kill target cells. In summary, purified SR/CR macrophages killed cancer cells in a non-ADCC manner via apoptosis induced by ROS and serine proteases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073402

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  18 in total

1.  Strain-specific susceptibility for pulmonary metastasis of sarcoma 180 cells in inbred mice.

Authors:  Haris G Vikis; Erin N Jackson; Alexander S Krupnick; Andrew Franklin; Andrew E Gelman; Qiong Chen; David Piwnica-Worms; Ming You
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 2.  Cooperativity of adaptive and innate immunity: implications for cancer therapy.

Authors:  Anil Shanker; Francesco M Marincola
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

3.  Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements.

Authors:  Anne M Sanders; John R Stehle; Michael J Blanks; Gregory Riedlinger; Jung W Kim-Shapiro; Arta M Monjazeb; Jonathan M Adams; Mark C Willingham; Zheng Cui
Journal:  BMC Cancer       Date:  2010-03-31       Impact factor: 4.430

4.  The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction.

Authors:  Gregory Riedlinger; Jonathan Adams; John R Stehle; Michael J Blanks; Anne M Sanders; Amy M Hicks; Mark C Willingham; Zheng Cui
Journal:  BMC Cancer       Date:  2010-05-03       Impact factor: 4.430

5.  Gene expression signature for spontaneous cancer regression in melanoma pigs.

Authors:  Florian Rambow; Guillaume Piton; Stephan Bouet; Jean-Jaques Leplat; Sylvain Baulande; Angelique Marrau; Mark Stam; Vratislav Horak; Silvia Vincent-Naulleau
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

6.  NORMAL TISSUE REACTIONS TO CHRONIC RADIATION EXPOSURE IN MAN.

Authors:  A V Akleyev
Journal:  Radiat Prot Dosimetry       Date:  2016-07-29       Impact factor: 0.972

7.  Novel innate cancer killing activity in humans.

Authors:  Michael J Blanks; John R Stehle; Wei Du; Jonathan M Adams; Mark C Willingham; Glenn O Allen; Jennifer J Hu; James Lovato; Istvan Molnar; Zheng Cui
Journal:  Cancer Cell Int       Date:  2011-08-03       Impact factor: 5.722

8.  Influenza a virus induces an immediate cytotoxic activity in all major subsets of peripheral blood mononuclear cells.

Authors:  Sanda Sturlan; Monika Sachet; Suzann Baumann; Irina Kuznetsova; Andreas Spittler; Michael Bergmann
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

9.  Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment.

Authors:  Antonio Brú; Juan-Carlos Souto; Sonia Alcolea; Rosa Antón; Angel Remacha; Mercedes Camacho; Marta Soler; Isabel Brú; Amelia Porres; Luis Vila
Journal:  Mediators Inflamm       Date:  2010-02-11       Impact factor: 4.711

10.  Immune cells from SR/CR mice induce the regression of established tumors in BALB/c and C57BL/6 mice.

Authors:  Janne Koch; Jann Hau; Jan Pravsgaard Christensen; Henrik Elvang Jensen; Morten Bagge Hansen; Klaus Rieneck
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.